Neuroimaging is one of the most promising research areas for detection of the earliest stages of Alzheimer’s disease. Using neuroimaging together with proteomics, researchers report in the Journal of Alzheimer’s Disease that a blood test may reflect the levels of beta amyloid protein in the brain — a hallmark of the disease [1]. The findings may eventually lead to a blood test that helps to predict the risk for developing Alzheimer’s disease.